Skip to main content
OpenTrials
Completed

NCT Number: NCT02743091

Idiopathic Pre-capillary Pulmonary Hypertension in ESKD Patients

This study investigates the prevalence and prognosis of idiopathic pre-capillary pulmonary hypertension (PH) in patients with end-stage kidney disease (ESKD).

Completed

Looking for future studies?

Notify Me

Key information

About this study

Pulmonary hypertension (PH) is a rare cardiovascular disease with progressive and fatal features. PH is classified into the 5 groups, and the prevalence of group 1 pulmonary arterial hypertension, including idiopathic and heritable, is 5 to 15 cases per one million adults and a median survival was reportedly three years. PH found in patients with end-stage kidney disease (ESKD) is classified into group 5, because the pathogenesis and clinical characteristics have not been clarified. The prevalence of PH in patients with ESKD was reportedly around 17~56% based on echocardiographic studies. In this study, we evaluated the incidence of idiopathic pre-capillary PH of ESKD patients by right heart catheterization, and examined the prognosis by following the occurrence of heart failure death.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Symptoms of dyspnea, hypotension (systolic blood pressure <90mmHg, or syncope.
  • Systolic pressure gradients in tricuspid valve of 40 mmHg or more.
  • In right heart catheterization, precapillary PH was defined as mean pulmonary arterial pressure (PAP) ≥25 mmHg, pulmonary vascular resistance (PVR) ≥3 wood unit, and pulmonary artery wedge pressure (PAWP) ≤15 mmHg.

Exclusion criteria

  • Patients with systolic left ventricular dysfunction (left ventricular ejection fraction [LVEF] <50%), mitral or aortic regurgitation of grade 2 or more, aortic or mitral surface <1.5 cm2, severe anemia (blood hemoglobin <9 g/dl), severe chronic obstructive pulmonary disease defined by percent predicted forced expiratory volume in one second <60%, or lung fibrosis were not enrolled in this study.
  • In right hear catheterization, PAP ≥25 mmHg and PAWP >15 mmHg were diagnosed as post capillary PH.

Treatment and study plan

Primary outcomes

  1. Number of patients of idiopathic pre-capillary hypertension

    Time frame: 14 years

Secondary outcomes

  1. Number of patients who died of heart failure

    Time frame: 14 years

Sponsors and collaborators

Lead sponsor

Toujinkai Hospital

Other

Registry information

Official study title

Idiopathic Pre-capillary Pulmonary Hypertension in Patients With End-stage Kidney Disease

Important dates

Study start
2001
Primary completion
2015
Study completion
2015
First posted
Apr 19, 2016
Registry last updated
Apr 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.